SAR

Clinical trials for SAR explained in plain language.

Never miss a new study

Get alerted when new SAR trials appear

Sign up with your email to follow new studies for SAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New allergy shot under safety review in 400 adults

Symptom relief Not yet recruiting

This study looks at how safe Stapokibart injection is for people with seasonal allergic rhinitis (SAR). About 400 adults will take part, and researchers will track any side effects. The goal is to see if the drug is safe enough for wider use.

Matched conditions: SAR

Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief

Last updated May 17, 2026 16:09 UTC

SAR

Get alerted when new SAR trials appear

New allergy shot under safety review in 400 adults